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VNSAnti-NMDA receptor encephalitis (ANRE) has been previously reported as a rare cause of nonconvulsive status
epilepticus (NCSE). Vagus nerve stimulation (VNS) is generally considered as a palliative treatment for patients
with drug-resistant partial-onset epilepsy. Here, we report a case of refractory NCSE that was terminated after
vagus nerve stimulator implantation. To our knowledge, similar cases have not been reported previously.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Anti-NMDA receptor encephalitis (ANRE) is a recently recognized
form of paraneoplastic encephalitis and characterized by dyskinesias,
psychosis, and seizures secondary to antibodies to the NR1–NR2B
heteromer of the NMDA receptor [1,2]. Seizures are present in approxi-
mately three-fourths of all patients [3,4], with a few reports of convul-
sive status epilepticus (SE) in adults. However, ANRE, as a cause of
generalized NCSE, is extremely rare, with 2 cases having been reported
so far in the literature [5,6]. Status epilepticus secondary to ANRE is
thought to respond less favorably than SE caused by any other etiologies
[7]. Vagus nerve stimulation (VNS) is generally considered as a pallia-
tive treatment for patients with drug-resistant partial-onset epilepsy
[8]. However, its role in the management of refractory SE has been pre-
viously reported in few case reports both in adults and in children and in
a very few case series [9–11]. Here, we report a case of refractory NCSE,
secondary to ANRE that was terminated after vagus nerve stimulator
implantation.
2. Case report
A previously healthy 46-year-old right-handedmanwas admitted to
the psychiatry ward after a one-week history of mild fever, behavioral
changes, headaches, and reported facial twitches. His initial CT of the
brain was negative. His neurological status continues to deteriorate,
with reported episodes of lip smacking and facial twitches. Therefore,
he was transferred to the medical ward. The neurology team was
consulted, and a lumbar puncture (LP)was suggested. The cerebrospinal. This is an open access article underﬂuid (CSF) analysis showed elevated white count of 521 per microliter,
98% lymphocytes, elevated protein of 51/dL, and a normal glucose
level. Polymerase chain reaction for the following viruses and bacteria
were negative: herpes simplex virus I and II, varizella zoster virus,
human herpes virus 6, cytomegalovirus, Epstein–Barr virus, enterovirus,
mycoplasma pneumonia, and TB bacillus. There were no oligoclonal
bands. The Gram stain was negative. A diagnosis of encephalitis was
made, and he was started on acyclovir, ceftriaxone, and vancomycin.
His initial EEG showed intermitted slowing of delta range over both
frontocentral head regions with faster frequency superimposed
representing extreme delta brush (Fig. 1). Hewas loadedwith phenyto-
in, and a brain MRI was requested. The MRI of the brain with and with-
out contrast was reported as normal. However, his neurological status
has worsened, and he started to desaturate. He was transferred to the
ICUwhere the neurology teamwas called to reevaluate him. Continuous
EEG recording (CEEG) was advised, and it showed a rhythmical slowing
over both frontocentral head regions with a clear evolution in voltage,
frequency, and ﬁeld consistent with nonconvulsive status epilepticus
(NCSE) (Fig. 2). This evolution of the EEGpattern becamemore apparent
when the EEG was compressed (Fig. 3). He was loaded with midazolam
whichwas titrated up to burst suppression. Twodays later, he continued
to have facial twitches, and his CEEG was still showing electrical SE pat-
tern. Levetiracetam was loaded and continued on a titrating dose of up
to 2000 mg twice per day and on phenytoin with a titrating dose of
350 mg/day, with close drug level monitoring, followed in 2 days by a
loading dose of valproic acid. Four days later, he continued to have epi-
sodes of facial twitches and lip smacking, andCEEGwas still showing the
previously reported pattern. The epilepsy teamwas consulted and they
advised loading with propofol which was titrated up to 50 mg/h.
However, every attempt to decrease the propofol would result in
worsening facial twitches and, in a number of occasions, breakthroughthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The initial EEG tracing demonstrates generalized rhythmic and semirhythmic delta frequency activity at 1 Hz with superimposed, frontally predominant bursts of rhythmic beta
frequency activity. High pass ﬁlter 1 Hz; low pass ﬁlter 70 Hz; notch ﬁlter off representing extreme delta brush.
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ical features andEEGpattern. A repeatMRI of thebrainwith andwithout
contrast remained normal. Anti-NMDA receptor in the serum was re-
quested, and an extensive search for a tumor was recommended but
did not reveal any pathology. While waiting for the results of anti-
NMDA receptor antibodies, IVIG was given over a 5-day course, along
with a pulse of steroids. He was loaded with pentobarbital titrated up
to burst suppression. However, breakthrough electrical SE was still ap-
parent every time the level of suppression is reduced, and midazolam
was restarted and titrated up to 12 mg/h. Over several weeks, his
neurological status had not changed. His repeat LP showed white
count of 24 per microliter and 90% lymphocytes. He continued on
both propofol and midazolam while pentobarbital was discontinued.Fig. 2. EEG obtained 4 days after admission showing generalized rhythmic delta activity. The e
100 μV.Topiramate was added and titrated over 2 days to a dose of 200 mg
twice per day. Still, his CEEG was showing SE pattern, and he continued
to have facial twitches. He also continued on a combination of high
doses of levetiracetam 4 g/day, topiramate 400 mg/day, phenytoin
400mg/day, valproic acid 3000mg/day, clonazepam 5mg/8 h, and phe-
nobarbital 200 mg/day. A week later, his neurological status had not
changed, and every attempt to reduce his anesthetics would result in re-
current clinical and electrical seizures. While in the ICU, his dose of phe-
nobarbital was increased up to 150 mg twice per day, and he continued
on propofol and midazolam. Intravenous magnesium sulfate was also
tried but without success. He was also tried on IV ketamine, but his
neurological status remained the same, and he continued to show the
SE pattern when the level of sedation is reduced. The result ofvolution of the EEG pattern is suggestive of NCES. The calibration mark represents 1 s and
Fig. 3. EEG from one 30-second epoch including the 10-second period represented in Fig. 2 demonstrating evolution of the ictal pattern over time. The calibrationmark represents 1 s and
100 μV.
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of IVIG was recommended over a 4-day duration, 2 weeks after the ﬁrst
IVIG course was completed. However, his neurological status has not
changed, and he remained in NCSE for 110 days, and a decision was
made, after extensive discussions with the patient's family, to try VNS.
A vagus nerve stimulator was implanted and interrogated to an output
current of 2.5 mA over 4 days. His duty cycle was set at 30 s on and
5min off. After 1 week of vagus nerve stimulator implantation, midazo-
lam was weaned off successfully over 3 days and followed 4 days later
by a weaning off propofol without any clinical or electrical seizure
recurrences. His CEEG showed no evidence of electrical SE pattern. His
neurological status continued to improve in the succeeding months
with no reported clinical seizures. The dosages of antiepileptic drugs
(AEDs) were gradually reduced one at a time. He was discharged
from the hospital after 8 months of rehabilitation on no AEDs with
mild–moderate cognitive impairment.3. Discussion
Our case is typical in many respects of the ANRE syndrome, with
a prodrome of headaches, fever, and confusion that progressed
rapidly to prolonged NCSE. Notably, however, male cases of ANRE
are quite rare. A recently reported case series attempted to differen-
tiate male ANRE from female ANRE and suggested that male patients,
similar to our case, present with early seizures, whereas behavioral
changes are more common as an early manifestation in female
patients [12].
Seizures are a common feature of ANRE [2,13,14] and occur in more
than two-thirds of patients (76/100) in a recently published large series
[1]. A few refractory cases of SE as a result of ANRE have been reported;
however, their details were not speciﬁed. Thus, the occurrence of refrac-
tory SE seems to be an uncommon presentation of ANRE. In general,
prolonged NCSE carries a poor prognosis, with a mortality rate of 56%
[15]. In our case, the initial EEG pattern of extreme delta brush is highly
suggestive of ANRE [16]. The rhythmic slowwaves of cyclically evolving
activity in frequency and spatial distribution, support the diagnosis of
NCSE. Furthermore, this pattern's response to high-dose midazolam
and its recurrences after reduction of the dosage further support that
diagnosis.There are 2 reported cases in the literature of NCSE in adults with
anti-NMDA receptor encephalitis, including a 35 year old with refractory
generalized NCSE and underlying ovarian teratoma [5] and a 19 year old
with generalized NCSE andmediastinal teratoma [6]. Nonconvulsive sta-
tus epilepticus in both cases has improved after tumor resection. Other
cases of ANRE may respond to IV immunoglobulin, cyclophosphamide,
or rituximab. Rituximab is not available in our institution, and cyclophos-
phamidewas not tried because the patient's family was afraid of its toxic
side effects. However, our patient's neurological status was refractory to
the 2 courses of IVIG therapy and to a high-dose methylprednisolone.
Furthermore, the lack of association with a tumor etiology in our case,
unlike females with this syndrome, is similar to previously reported
studies describing a low frequency of paraneoplastic etiology in the
male population with this syndrome, accounting for 3% to 15% of
cases [12,17].
Nonconvulsive status epilepticus in our patient was highly resistant
to AEDs and anesthetic agents, and responded only after the implanta-
tion of a vagus nerve stimulator. To our knowledge, this is the ﬁrst re-
ported case of refractory NCSE as result of ANRE that responded to
VNS. Vagus nerve stimulation has been found to be effective to termi-
nate SE in several case reports. More recently, a well-described study
of eight patients with recurrent SE in Spain reported a signiﬁcant im-
provement of seizures after VNS, with four of the eight patients remain-
ing free of new episodes of SE after implantation, and in two additional
patients, the frequency decreased by N75% [18].
It is not clear why VNS was successful in acutely terminating SE in
our patient, when the other agents that are typically used to terminate
SE have failed. The precise mechanism of action of VNS as a
neuromodulatory treatment for epilepsy is still unknown, but its efﬁca-
cy seemsmainly based on an incremental effect [19]. On the other hand,
early animal experiments described an abortive effect of VNS in acute
seizure models [20]. As a treatment modality for both chronic and
acute epilepsy, several recent clinical and functional neuroimaging
studies have demonstrated that VNS induces an increase of cerebral
blood ﬂow (CBF) in several subcortical regions, mainly the thalamus,
the hypothalamus, the insula, and the cerebellum [21–23]. It is likely
that the alteration of transsynaptic neurotransmission related to the bi-
lateral thalamic CBF modiﬁcation results in the inhibition of the
corticothalamic relays, through a synaptic depolarization shift. Recent-
ly, it has been suggested that a possible role of the vagus nerve is
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to 6 months of VNS therapy for refractory epilepsy showed signiﬁcant
lower levels in IL-8 induction by lipopolysaccharide-stimulated periph-
eral blood mononuclear cells [24]. This altered cytokine response after
long-termVNS could be implied in the efﬁcacy of this therapy to reduce
the frequency of seizures and SE, based on the hypothesis that brain in-
ﬂammation plays a role in the mechanisms of hyperexcitability occur-
ring during repetitive or prolonged seizures [25].
Finally, the natural course of the patient's illness cannot be excluded
as the cause of remission. However, refractory SE is rarely reported to
improve spontaneously. It is also possible that the response to VNS
might be as a result of delayed response from immunotherapy. This pos-
sibility seems very unlikely given the long lag between our patient's sec-
ond dose of IVIG and his clinical and electrical improvement. In most
cases of ANRE, the response to immunotherapy occurs within weeks
and, very rarely, after several months of treatment, and in most cases
following resection of the culprit tumors. It may also be hypothesized
that in our case, VNS may have exerted its acute seizure effect through
a direct or indirect effect on the NMDA receptor modulations in various
brain lesions including the hippocampus and forebrain that are known
to be rich in NMDA. Interestingly, an animal model of absence seizures
shows increased expression of NMDA receptors in the thalamus, and
drugs that blockNMDA in the thalamuswere shown to have antiseizure
effect in that model [26]. It is likely that VNS, through its modulating
effect in the thalamus, modulates these receptors; hence, this may
explain its acute seizure effects.
4. Conclusions
This case illustrates the need to consider anti-NMDA receptor en-
cephalitis as a cause of refractory status epilepticus should associated
clinical features suggestive of this syndrome be present. Additionally,
our paper suggests that adult male patients who present with seizures,
normal MRI, and no clear etiology should be tested for NMDA receptor
antibodies to avoid any delay in treatment initiation. Continuous EEG
monitoring is crucial to the diagnosis of NCSE and to monitor the effect
of various treatment modalities on ictal EEG recordings. We propose
that vagus nerve stimulator implantation should be considered in
cases of NCSE, and possibly, for convulsive SE that is resistant to stan-
dard pharmacotherapy. Future studies are needed to determine the
efﬁcacy of VNS in this setting and to optimize the timing of device
placement and stimulation parameters for similar cases.
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